L Stock Recent News

Loews: At $87 It's Undervalued Given Management's Persistent History Of Success

NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable March 11, 2025 to shareholders of record as of the close of business on February 26, 2025. Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries.

7.7 MILLION COMMON SHARES REPURCHASED IN 2024 FOR $611 MILLION NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its fourth quarter 2024 financial results. Fourth Quarter 2024 highlights: Loews Corporation reported net income of $187 million, or $0.86 per share, in the fourth quarter of 2024, compared to $446 million, or $1.99 per share, in the fourth quarter of 2023.

NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) will report fourth quarter 2024 financial results on Monday, February 10, 2025. On that date the Company will also post earnings remarks on its website.

NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) will report third quarter 2024 financial results on Monday, November 4, 2024. On that date the Company will also post earnings remarks on its website.

Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).2 It will be available for all IV indications of Tecentriq approved for adults in the U.S., including certain types of lung, liver, skin and soft tissue cancer.3

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV i.

NEW YORK , Sept. 9, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today that the Delaware Court of Chancery found no liability in connection with Loews's 2018 acquisition of the minority limited partner interests in its Boardwalk Pipelines subsidiary.

NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 3, 2024 to shareholders of record as of the close of business on August 21, 2024. Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries.

I'm a big fan of Berkshire Hathaway (NYSE: BRK-A , BRK-B ) and Warren Buffett. As a result, I've become a big fan of holding company stocks.